Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


 

ECCMID 2019: new guideline on invasive fungal infections

25/04/2019

A dedicated working group of the European Society of Clinical Microbiology and Infectious Diseases is developing a new guideline on invasive fungal infections, which could be of particular relevance for the ICU population. Despite the guideline still being in an early phase, prof. Cornelia Lass-Flörl, who is actively involved in this new guideline, was eager to share some details on the background, methodology, contents, usefulness and expected timelines of this guideline.    This editorially independent interview has been financially sponsored by Gilead.

  • 00:08:54
 

EMUC 2018: Take home messages

12/12/2018

Dr. Laurence Albiges, medical oncologist at the Institut Gustave Roussy (France), shares with us her take home messages of EMUC 2018, several of which might have practice changing potential. 

  • 00:05:17
 

ASH 2018: Highlights lymphoma

11/12/2018

Dr. Martin Hutchings from Denmark talks about the first in-human trial he presented at ASH 2018 and mentions another congress highlight: the ECHELON-2 trial.

  • 00:04:13
 

ESMO 2018 in depth: Abiraterone plus prednisone in high and low risk metastatic hormone naïve prostate cancer

06/11/2018

Alex Hoyle, oncologist at the Christie and Salford Royal Hospitals in Manchester, provides information on the effects of abiraterone plus prednisone in high and low risk metastatic hormone naïve prostate cancer patients.   

  • 00:02:54
 

Quarterly Focus on Hematology | CLL

10/01/2019

Treating patients with chronic lymphocytic leukemia in an optimal fashion seems to become more complex every day. After all, our knowledge of the underlying biological complexity keeps on growing, creating new subgroups of patiets, and on top of that new potential drug combinations are constantly being developed and presented. In this program, a very international discussion panel will guide you through 2 highly relevant publications, helping you better understan the latest developments in the field of CLL. Guests Prof. Arnon Kater, MD, PhD Hematologist, Amsterdam UMC (AMC), The Netherlands Prof. Stephan Stilgenbauer, MD Hematologist, Saarland University, Homburg & Ulm University, Ulm, Germany Gert Jan Timmers, MD, PhD Hematologist, Amstelland Ziekenhuis, Amstelveen, The Netherlands Prof. Paolo Ghia, MD, PhD Internist, Università Vita-Salute San Raffaele, Milan, Italy Kostas Stamatopoulos, MD, PhD CERTH, Thessaloniki, Greece   Publications to be discussed Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study - Kater et al., JCO, december 2018 Cytogenetic Complexity in Chronic Lymphocytic Leukemia: Definitions, Assiciations and Clinical Impact - Baliakas et al, Blood, January 2019 About our "Quarterly Focus" format Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data.  

 

Quarterly Focus on GU | Bladder Cancer

21/11/2018

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. In this third episode of the Quarterly Focus on Genitourinary Cancer, two pivotal, international publications on Bladder Cancer from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. The expert panel consist of: Michiel van der Heijden, MD, PhD - medical oncologist, Netherlands Cancer Institute, Amsterdam Prof. Fred Witjes, MD -  urologist, Radboudumc, Nijmegen Sjoukje Oosting, MD, PhD - medical oncologist, UMCG, Groningen Program: Speaker: Prof. Dipen Parekh, MD – urologist at University of Miami Health System in Miami, USA Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial Lancet 391, 2018 Speaker: Michiel van der Heijden, MD, PhD, medical oncologist, Netherlands Cancer Institute, Amsterdam, The Netherlands Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial Lancet 391, 2017

 

Quarterly Hematology: highlights in Hodgkin Lymphoma

11/10/2018

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. Two high-impact international publications on Hodgkin Lymphoma of the past year will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. During this live broadcast you will have the unique opportunity to interact with our expert panel and the authors and ask them your questions. The expert panel consists of: Josée Zijlstra, MD, PhD, hematologist, VUmc Amsterdam Wouter Plattel, MD, PhD, hematologist, UMC Groningen Live video guests: HD18: Prof. Peter Borchmann, MD, PhD, hematologist, University Hospital of Cologne, Germany H10: Prof. Massimo Federico, MD, hematologist, University of Modena and Reggio Emilia, Italy

Click here to select your areas of interest

Areas of interest

Select to filter on program types

Congresnieuws 30/04/2019

ECCMID 2019

From April 13th - 16th, Amsterdam hosted the 29th European Congress of Clinical Microbiology & Infectious Diseases. With thousands of abstracts being discussed, it was easy to miss out on some developments. Invasive fungal diseases still pose many diagnostic and therapeutic challenges. Therefore, MEDtalks asked several top experts to come up with their personal (congress) highlights regarding this challenging topic, and focus on translating scientific developments to clinical practice. Topics and speakers Impact of new immunomodulators on the risk and management of invasive fungal infections by prof. Dimitrios Kontoyiannis, MD, PhD Management of invasive fungal infections by prof. Johan Maertens, MD, PhD New ESCMID guideline on invasive fungal infections by prof. Cornelia Lass-Flörl, MD, PhD The diagnosis of invasive fungal infections by prof. Katrien Lagrou, PharmD, PhD  

Congresnieuws 25/04/2019

ECCMID 2019: new guideline on invasive fungal infections

A dedicated working group of the European Society of Clinical Microbiology and Infectious Diseases is developing a new guideline on invasive fungal infections, which could be of particular relevance for the ICU population. Despite the guideline still being in an early phase, prof. Cornelia Lass-Flörl, who is actively involved in this new guideline, was eager to share some details on the background, methodology, contents, usefulness and expected timelines of this guideline.    This editorially independent interview has been financially sponsored by Gilead.

Congresnieuws 25/04/2019

ECCMID 2019: immunomodulators and invasive fungal infections

Oncology treatment has come a long way. Prof. Dimitrios Kontoyiannis first discusses the recent changes in oncology treatment and their respective impact on the risk of invasive fungal infections. Then he adresses which emerging patient populations in the (hemato-)oncology setting are at an increased risk of infections. How do we properly identify them and what are the challenges in treatment of these patients?   This editorially independent interview has been financially sponsored by Gilead.

Congresnieuws 25/04/2019

ECCMID 2019: management of invasive fungal infections

Managing invasive fungal diseases is a dynamic expertise. In this interview, prof. Johan Maertens talks about the changing fungal landscape, both in terms of the host (i.e. haematological patients) as the type of fungal pathogen. Looking at these changes: what are the relevant challenges and therapeutic opportunities?   This editorially independent interview has been financially sponsored by Gilead.

Congresnieuws 25/04/2019

ECCMID 2019: the diagnosis of invasive fungal infections

Invasive fungal diseases still pose many diagnostic challenges. MEDtalks asked prof. Katrien Lagrou to elaborate on some challenges that particularly concerned her, and to scour the ECCMID 2019 program for interesting (future) diagnostic developments.   This editorially independent interview has been financially sponsored by Gilead.

Nascholingen 04/03/2019

E-learning: Update on Renal cell carcinoma with prof. Camillo Porta

During a special Speaker Tour meeting prof. Camillo Porta visited the NKI-AVL to discuss challenges and best practices within the changing treatment landscape in (m)RCC.  ‘With the development of new therapeutic systemic options for the treatment of mRCC, including immunotherapy, novel TKIs and combination treatment, we find ourselves standing at the verge of a new era of therapeutic possibilities.  Our challenge is to find the best possible treatment algorithm for each (m)RCC patient.’ Topics that are discussed in this e-learning are: When are we ready for adjuvant therapy? What is the role of cytoreductive nephrectomy in mRCC? How to choose from the available options for first, second, and third line treatment? What may be the impact of immunotherapy and novel TKIs on the treatment algorithm? Chair and co-discussant: prof. J. Haanen, medical oncologist, NKI-AVL

Meet the author 17/12/2018

Quarterly Focus on Genitourinary Cancer: highlights in prostate cancer (part 2)

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. In this third episode of the Quarterly Focus on Genitourinary Cancer, two pivotal, international publications on Bladder Cancer from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. The expert panel consist of: Niven Mehra, MD, PhD – medical oncologist, Radboudumc, Nijmegen Andre Bergman, MD, PhD – medical oncologist, Netherlands Cancer Institute, Amsterdam Prof. Theo de Reijke, MD - urologist, Amsterdam UMC, Amsterdam Program: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer (LATITUDE) N Engl J M, July 27, 2017 Speaker: Karim Fizazi, MD, PhD - medical oncologist, Gustave Roussy Institute, Villejuif, France Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial The Lancet, Oct 21, 2018 Speaker: Prof. Nicholas James, PhD - medical oncologist, University of Birmingham, UK

Congresnieuws 13/12/2018

EMUC 2018: Radiomics

Prof. Philippe Lambin, radiation oncologist at the University of Maastricht (the Netherlands), and dr. Jochen Walz, urologist at the Institut Paoli-Calmettes (France), are enthousiastic about radiomics. This tool is developed to standardize radiologic examinations as a means to become independent of personal performance.

Congresnieuws 13/12/2018

EMUC 2018: Best Abstract Award

Dr. Christian Fankhauser, urologist at the UniversitätsSpital Zürich in Switzerland, has won the Best Abstract Award at the EMUC 2018. He is currently testing an algorithm designed to standardize tissue examination in order to get more uniformity in the Gleason Score assessment.

Congresnieuws 13/12/2018

EMUC 2018: Highlights

Prof. Alberto Briganti, professor in the urology at the IRCCS Ospedale San Raffaele in Italy, is a member of the EMUC scientific committee on behalf of the EAU. He shares with us his personal highlights of the EMUC 2018, among which are the STAMPEDE and HORRAD trials and new radiological developments.

Congresnieuws 13/12/2018

EMUC 2018: HORRAD trial

In the HORRAD trial patients with prostate cancer were randomized to receive either local therapy and ADT or ADT alone. Dr. Liselotte Boevé, urologist at VU Medisch Centrum in Amsterdam, presents us the results.